Annovis Bio publishes Alzheimer's trial results in Nature journal
Annovis Bio Inc. (NYSE: ANVS) announced the publication of its Phase 2/3 Alzheimer's disease trial results in the peer-reviewed journal ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
